-
2022-501863-41-00
5
2023-11-13
Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
-
2023-503422-39-00
5
2023-10-20
Hepatocellular Carcinoma (HCC)
-
2022-501352-28-00
5
2023-06-07
Severe community-acquired pneumonia (sCAP)
-
2022-501608-85-00
5
2023-05-09
Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
-
2022-501217-31-00
10
2023-03-09
Hepatocellular carcinoma
-
2023-505628-67-00
5
2022-10-28
Relapsed and Refractory Follicular Lymphoma
-
2024-513882-38-00
10
2022-10-12
Intermediate stage Hepatocellular carcinoma
-
2024-516403-16-00
5
2022-04-07
Adult patients with immune thrombocytopenia (ITP) with mild to severe
-
2024-512634-15-00
9
2022-01-05
Patients with untreated mantle cell lymphoma
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-505807-21-00
5
2021-11-16
Relapsed/refractory follicular lymphoma
-
2024-513936-80-00
4
2021-11-12
elderly patients (> 70 years) with CLL or SLL
-
2024-511658-28-01
5
2021-04-06
primary sclerosing cholangitis
-
2024-513252-15-00
4
2021-01-28
IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
-
2024-512232-30-00
10
2021-01-18
Primary Biliary Cholangitis
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2024-512269-14-00
5
2020-01-27
GIant cell Arteritis
-
2023-504303-86-00
5
2019-11-21
High-risk hepatocellular carcinoma (HCC)
-
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
-
2024-512555-21-00
5
2019-09-18
Metastatic colorectal cancer
-
2024-514348-95-00
5
2019-06-24
Intrahepatic non-cirrhotic portal hypertension
-
2024-516048-24-00
4
2019-06-19
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST
-
2023-509216-28-00
4
2019-05-27
Generalized Pustular Psoriasis
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia